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Summary We have identified a high frequency of loss of heterozygosity (LOH) on the human chromosome region 8p12-p22 in a panel of
microdissected familial (86% LOH) and sporadic (74% LOH) breast tumours. The two most frequently deleted regions were defined around
marker D8S133 and in a broader centromeric region bounded by markers D8S137 and D8S339. We cannot unequivocally characterize the
8p12-p22 loss as an early or a late event in breast carcinogenesis. In parallel, we have performed linkage analysis in four German breast
cancer families. A location score greater than 13.67 corresponding to a LOD score of 2.97 at the marker D8S137 has been obtained. Our
results considerably strengthen the evidence for a breast cancer susceptibility gene(s) located on the short arm of the chromosome region at
8p12-p22.
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The short arm of chromosome 8 is the site of frequent loss of
heterozygosity (LOH) in different types ofhuman cancer (Spurr et
al, 1995), including prostate (Macoska et al, 1995; Vocke et al,
1996), colon (Yaremko etal, 1994; Farrington et al, 1996), bladder
(Takle and Knowles, 1996), liver (Emi et al, 1992), lung (Ohata et
al, 1993), ovarian (Cliby et al, 1993), oesophageal (Shibagaki et al,
1994) and breast cancer (Chuaqui et al, 1995; Kerangoueven et al,
1995; Imbert et al, 1996; Yaremko et al, 1996). In several studies,
the 8p losses have been mapped to two or more distinct regions in
these cancers.
Deletion mapping in colorectal cancer has suggested that a
region spanning 8p23.2-p22 and a more centromeric region at
8p21.3-pil .2 are lost in more than 50% of sporadic colorectal
cancers (Cunningham et al, 1993; Farrington et al, 1996).
Similarly, studies in prostate cancer indicate two regions of 8p
losses at 8p22 and a more proximal region at 8p2l-pl2 (Macoska
et al, 1995; Bova et al, 1996; Vocke et al, 1996). Two independent
regions of loss are also supported by mapping data in the
other cancers mentioned above. A common region of LOH at
8p2l.3-p22 in colon, lung and liver cancers has been described by
Fujiwara et al (1994).
Several investigations have found allelic loss of 8p to be asso-
ciated with a more advanced clinical stage and invasive behaviour
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in these neoplasms (Knowles et al, 1993; Suzuki et al, 1995;
Yaremko et al, 1996). Furthermore, the metastatic potential of a
rat prostatic cancer cell line as well as the tumorigenicity and
invasiveness of colon carcinoma cell lines have been suppressed
by introduction of a normal human chromosome 8 and the short-
arm region 8pl2-pter respectively (Ichikawa et al, 1994; Tanaka
et al, 1996). Together, these data strongly suggest that one or
more tumour-suppressor gene(s) involved in several epithelial
neoplasms are located on 8p.
Allelic loss of 8p has not been investigated extensively in
breast cancer. However, recent studies identified 8p LOH in
more than 50% of sporadic breast cancers occurring in regions
of 8p similar to other cancers (Kerangoueven et al, 1995; Imbert
et al, 1996; Yaremko et al, 1995, 1996). The most frequent
deleted regions were detected with markers D8S258, D8S133
and D8S259, located at 8pl2-p22 (Kerangoueven et al, 1995;
Imbert et al, 1996), but also with markers D8S254 (8p22) and
NEFL (8p2l) (Yaremko et al, 1995, 1996). In addition, LOH in
two distinct 8p areas (8pl2-p2l.3, 8p22) has been found in
more than 80% of male breast cancer (Chuaqui et al, 1995). In
familial breast cancer, Lindblom et al (1993) reported 8p LOH
in about 20% of familial breast tumours using markers located
telomeric to those markers used by other groups.
To clarify LOH patterns on 8p in familial breast cancer, we
performed LOH analysis in a large number of familial breast
cancers. The same set of microsatellite markers was studied in a
similar number of sporadic breast tumours for direct comparison
(Dib et al, 1996; Imbert et al, 1996). In addition, we studied a
possible linkage between markers from this genomic region and
breast cancer families unlinked to BRCAI and BRCA2.
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Table 1 Characterization of breast cancerfamilies
Family number Average age at diagnosis Number and type of different cancers in the families
of breast cancer (years)
MDC29 34.5 2 Breast, pancreas
MDC30 51.1 2 Breast, stomach
MDC31 53.0 1 Breast
MDC32 42.5 4 Breast, bladder, uterus, unknown
MDC36 64.0 2 Breast, uterus
MDC38 49.0 3 Breast, colon, kidney
MDC39 57.4 3 Breast, lung, oesophagus
MDC42 40.3 3 Breast, ovary, uterus
MDC44 49.7 2 Breast, endometrium
MDC52 55.0 2 Breast, leukaemia
MDC56 54.0 4 Breast, liver, lung, uterus
MDC58 63.7 2 Breast, lung
MDC59 52.0 5 Breast, prostate, liver, lung, kidney
MDC60 43.3 6 Breast, ovary, stomach, uterus, bone, endometrium
MDC64 53.7 3 Breast, liver, uterus
MDC65 61.0 2 Breast, stomach
MDC67 60.7 4 Breast, stomach, lung, uterus
MDC71 56.8 4 Breast, pancreas, uterus, leukaemia
MDC73 41.6 4 Breast, stomach, kidney, oesophagus
MDC74 55.5 2 Breast, uterus
MDC75 46.5 1 Breast
MDC79 69.3 1 Breast
MDC81 49.8 1 Breast
MDC94 55.3 6 Breast, ovary, colon, lung, uterus, bladder
MDC95 54.3 2 Breast, ovary
MDC101 36.7 1 Breast
MDC102 44.0 3 Breast, liver, leukaemia
MDC106 50.3 4 Breast, lung, uterus, brain
MDC1363 53.3 3 Breast, liver, skin
I=29
MATERIALS AND METHODS
Families
Forty-eight German families (MDC families) with familial cancer,
predominantly breast cancer, were collected at the Department of
Tumour Genetics of the Max Delbrueck Center Berlin-Buch,
Germany. Details ofthese families are documented in Tables 1 and
2. Blood samples and tumour specimens were coded, and the
confidentiality of the clinical information was preserved. The
study was performed with the approval of the local ethics
committee.
Tumour and blood samples
Tumour specimens from MDC families were retrieved from
pathology archives. Of the 44 tumours, 27 were invasive ductal
carcinoma (IDC), six were invasive lobular carcinomas (ILC) and
seven were non-invasive tumours, including six ductal carcinomas
in situ (DCIS) and one lobular carcinoma in situ (LCIS).
Paraffin-embedded samples of human primary breast tumours
and normal tissues were from consecutive patients who had
undergone mastectomy at the Robert Roessle Clinic Berlin-Buch,
Germany. The 50 sporadic tumours comprised 40 IDC, seven ILC,
one medullary, one mucinous and one papillary carcinoma.
The pathology records of the familial and sporadic cases were
reviewed by an independent pathologist and were microdissected
after a modification of published procedures (Greer et al, 1994).
For each case, a representative tissue block was identified that
contained the maximum density of tumour cells. An initial 4-jim
pilot section was obtained, followed by ten consecutive 10-,um
sections and a final 4-jm pilot section. Special care was taken to
mount sections in the same orientation and without tissue distor-
tion. The intervening sections were deparaffinized in xylene, rehy-
drated in descending ethanol and dried. The flanking pilot sections
were stained withhaematoxylin andeosin and the tumourcell-rich
areas with minimal stromal component were marked. The corre-
sponding areas on the consecutiveunstained sections were isolated
with a sterile hypodermic needle under a dissecting microscope
and transferred into 10-50jl ofextraction buffer [1 mm Tris-HCl
pH 7.5, 1% (v/v) Triton X100]. The suspension was supplemented
with 5-25 jl ofproteinase K (20 mg ml-'; Boehringer Mannheim,
Germany) and digested at 37°C for a minimum of 16 h followed
by heat inactivation ofthe enzyme at 99°C for 10 min. Similarily,
non-tumorous DNA was extracted from tumour cell-free adjacent
tissue or lymph nodes. Between 1 and 5 jl of the extraction
volume was used for subsequent detection ofLOH.
EDTA blood samples were obtained for the extraction of
genomic DNA, which was isolated from whole blood by standard
procedures.
Detection of LOH
The oligonucleotide primers for the seven polymorphic markers
used in this study were synthesized according to published primer
sequences (GDB; Kerangoueven et al, 1995; Dib et al, 1996).
Polymerase chain reactions (PCR) were carried out with 40 ng of
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Table 2 Clinical and histopathological data on patients and tumours from breast cancer families
Family number ID Tumour type Age at diagnosis of Overall survival Patient's status Disease-free survival
breast cancer (years) (years) (years)
MDC29
MDC30
MDC31
MDC32
MDC36
MDC38
MDC39
MDC42
MDC44
MDC52
MDC56
MDC58
MDC59
MDC60
MDC64
MDC65
MDC67
MDC71
MDC73
MDC74
MDC75
MDC79
MDC81
MDC94
MDC95
MDC101
MDC102
MDC106
MDC1 363
300
300
303
300a
301a
302a
300
300
300
300
304
301
300
300
302
300
301
300
302
302
401
402
415
416
203
300
300
300
306
300
300
300
300
203
302
300
307
300
200
300
302
200
306
302
£= 29
ILC
IDC
IMC
IDC
NIC
NIC
IDC
IMC
IDC
ILC
IDC
IDC
IDC
IMC
IDC
IDC
ITC
NIC
NIC
ILC
IDC
IDC
ILC
IDC
IDC
IDC
IDC
IDC
IDC
IDC
IDC
IDC
IDC
IDC
NIC
NIC
ILC
IDC
IDC
IDC
IDC
NIC
ILC
IDC
NIC = 7
IDC = 27
ILC= 6
IMC = 3
ITC= 1
33
49
46
49
54
57
33
55
43
58
72
44
59
52
50
54
70
55
59
55
39
28
47
28
79
48
51
37
51
37
55
40
50
81
39
66
35
49
31
33
46
53
46
35
31
4
4
3
2
6
11
5
2
9
12
2
4
7
3
2
7
3
7
4
9
3
4
2
9
3
13
3
3
10
5
2
3
16
4
26
4
2
6
1
1
Alive
Dead
Alive
Dead
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Dead
Dead
Alive
Alive
Dead
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Dead
Alive
Alive
Alive
Alive
Dead
Alive
Alive
23
4
4
3
2
1
11 5
11
5
.2
9
12
2
4
7
3
2
1
6
2
5
4
9
3
4
2
4
3
8
3
3
10
5
2
3
14
4
21
4
2
6
1
1
aMale breast cancer. NIC, non-invasive carcinoma; IDC, invasive ductal carcinoma; ILC, invasive lobularcarcinoma; IMC, invasive medullarcarcinoma; ITC,
invasive tubular carcinoma.
DNA in PCRbuffer (Perkin Elmer, Foster City, LA, USA), 0.5 gM
ofeach primer, 200gM ofdNTPs and 0.5 units of Taq polymerase
(Perkin-Elmer). The forward primer of each set was end labelled
before reaction with [y-32P]dATP (Amersham, Aylesbury, UK)
using T4 polynucleotide kinase (Boehringer, Mannheim,
Germany). After a 5-min denaturation at95°C, 30 cycles ofampli-
fication were carried outusing cycling parameters of94°C for 15 s
(D8S133, NEFL), 30 s (D8S131, D8S505, D8S259, D8S137) or 1
min (D8S339), 42°C for 1 min (D8S339), 520C for 30 s (D8S137),
55°C for 15 s (D8S133, NEFL), 55°C for 30 s (D8S259) or 60°C
for 15 s (D8S131, D8S505), 72°C for 15 s (D8S133, NEFL,
D8S137) 72°C for 30 s (D8S259, D8S131, D8S505) or 72°C for
2 min (D8S339), with a final extension of 10 min at 72°C.
Reaction products were fractionated on a 7% denaturing polyacry-
lamide gel. After electrophoresis, gels were dried at 80°C and
exposed to radiographic film for 10-48 h at room temperature. All
reactions from each subject were repeated under the same condi-
tions at least twice. Primer sequences of BRCA1 markers
(D17S250, D17S588 and D17S579) and of BRCA2 markers
(D13S289, D13S260 and D13S267) used for amplifications were
available from GDB. The reaction was started after a 5-min
denaturation of DNA at 95°C. Thirty cycles of amplification for
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D17S250 (94'C 30 s, 55°C 30 s, 72°C 1 min), D17S579 (94°C
30 s, 55°C 30 s, 72°C 1 min), D17S855 (94°C 30 s, 60°C 30 s,
72°C 1 min), D13S289 (94°C 30 s, 58°C 30 s, 72°C 1 min),
D13S260 (94°C 30s, 60°C 30s, 72°C 1 min) and D13S267 (94°C
30 s, 58°C 30 s, 72°C 1 min) were followed by a final extension of
10 min at 72°C.
The criteria for LOH was complete or near complete loss ofone
allele in the tumour DNA compared with the normal control, as
determined by visual inspection (Figure 1).
Statistical analysis was performed using ax2 (Fisher exact) test,
with P values <0.05 considered to be statistically significant.
Linkage analysis
Microsatellite typing was performed using standard procedures. To
establish the probability that a family was linked to BRCAJ, allelo-
typing was performed using the BRCAJ flanking or intragenic
microsatellite markers D17S250, D17S588 and D17S579. Linkage
to BRCA2 was assessed using the chromosome 13 markers
D13S289, D13S260 and D13S267. Linkage analysis for 8pl2-p22
was performed using the seven markers described in the text.
The penetrance and gene frequencies are based on the CASH
model (Claus et al, 1991, 1993).
Linkage calculations were performed using the program
MLink of Fastlink (Cottingham et al, 1993) and Vitesse
(O'Connel et al, 1995).
RESULTS
Identification of loss of heterozygosity in familial and
sporadic breast tumours
A total of44 familial breast tumours from 29 different families and
50 sporadic breast tumours were examined for LOH with seven
polymorphic microsatellite markers covering the chromosome
region 8pl2-p22. The order of the markers, i.e. D8S133, NEFL,
D8S131, D8S137, D8S339, D8S259 and D8S505, was derived
from existing consensus maps and the most recent literature (Spurr
et al, 1995; Dib et al, 1996; Imbert et al, 1996; Yu et al, 1996). All
cases were informative for at least one marker. Overall, 86.4% of
informative familial and 74% of informative sporadic tumours
showed LOH for at least one marker on chromosome region
8pl2-p22. The results ofthe LOH analysis are presented in Figure
2A and B and Tables 3 and 4. The most frequently deleted region
in familial breast cancer was observed with markers D8S133 in the
telomeric region (52% LOH) and with markers covering the
central part of 8pl2-p22 at D8S131 (52% LOH), D8S137 (54%
LOH) and D8S399 (48% LOH), (Figure 2C and Table 4). Familial
breast tumours were also analysed for LOH at BRCAI and BRCA2
markers. Ofthe informative cases, 64.7% and 50.0% showed LOH
in these chromosomal regions encompassing BRCAJ and BRCA2
respectively (Table 3). Interestingly, a number of tumours showed
concomitant allelic loss of all three chromosomal regions
(8pl2-p22, 17q21 and 13q13).
In sporadic breast tumours, the most frequent losses involved
the telomeric markers D8S133 (48% LOH) and NEFL (41%
LOH), followed by the marker D8S137 (45% LOH) and the
more centromeric marker D8S339 (39% LOH) (Figure 2B and C,
Table 4). In comparison to the sporadic cancers, familial tumours
showed a similar pattern of loss, yet at a frequency of up to 17%
higher (for marker D8S131) than the sporadic cases.
Linkage analysis of breast cancer families with
chromosome region 8p12-p22 microsatellite markers
The high frequencies of LOH detected at microsatellite loci from
the chromosomal region 8pl2-p22 in familial and, to a lesser
extent, sporadic breast tumours prompted a focused linkage
analysis. Of the 48 German families collected in the course of a
nationwide project (Zimmermann et al, 1993; Jandrig et al, 1996),
12 yielded negative LOD scores for markers within or closely
linked to the BRCAJ and BRCA2 genes (Table 5). These twelve
families, likely to be unlinked to either BRCA1 and BRCA2, were
selected for genetic linkage analysis using tie three 8pl2-p22
markers D8S133, NEFL and D8S259, which showed the highest
percentage of LOH (Table 4). A Linkmap-multipoint linkage
yielded a positive LOD score for these markers in four of the
twelve families (families 20, 59, 60 and 81) (Figure 3 and Table 5).
Extending the linkage analysis to D8S 137, D8S131 and D8S339
produced a location score greater than 13.67, corresponding to a
LOD score of 2.97 (Figure 2). A single peak was observed at
markers D8S137/D8S131 flanking a nadir at D8S339, which is due
to a recombination event in family 60 (individual 415).
These linkage data provide further support for a novel breast
cancer susceptibility locus located to the approximately 20-cM
interval between NEFL and D8S505 (Kerangouven et al, 1995;
Imbert et al, 1996).
Correlation of clinical and histopathological parameters
with 8p12-p22 allelic loss in familial breast cancer
The 44 microdissected familial tumours included seven non-
invasive (NIC) and 37 invasive carcinomas (IC), thus allowing the
investigation ofthe relation of 8p deletions to the state ofinvasive-
ness. All tumours were informative for at least one 8p marker. All
non-invasive carcinomas (7 out of 7, 100%) and 31 of the 37
invasive carcinomas (83.8%) showed LOH with one or more 8p
marker, a difference not statistically significant at the P < 0.975
level. This trend could suggest a preferential involvement of 8p
LOH in tumours progressing towards invasion via an intraductal
stage, whereas primary invasive cancers may at least partly depend
on somatic events not involving the short arm ofchromosome 8.
With regard to histotypes, 22 of the 27 invasive ductal carci-
nomas (81.5%) and all ofthe invasive lobular carcinomas (7 out of
7, 100%) showed LOH with at least one marker, a difference not
statistically significant at the P < 0.9 level. Again, this trend may
suggest that 8p loss is potentially involved in the determination of
the tumour growth pattern.
There was no correlation between 8p LOH and tumour size,
grade, ER status, overall and disease-free survival, age of onset of
the breast cancer or presence of metastases (all P > 0.1). Also, no
correlation was found between 8p LOH and the presence of LOH
around BRCAJ, BRCA2 or both.
We have divided the breast cancer families into groups, according
to the type of tumours observed: breast cancer-only families (BC),
families with breast and ovarian cancer (BOC) and families with
various other cancers in addition to breast cancer (VOC). All the
tumours from the five BC families (9 out of 9; 100%) showed 8p
LOH with at least one marker, whereas 29 ofthe 35 (82.8%) breast
carcinomas from 24 VOC families demonstrated 8p deletions. In
the BOC families, the only tumour studied displayed 8p LOH.
Although the numberoflosses in the family groups was too small to
give significant results by X2 analysis (P> 0.7), a trend towards a
predominance of8p losses in BC families is apparent.
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Figure 1 Examples of LOH. Representative examples of allelic loss in familial and sporadic breast cancer at different loci of the chromosomal region
8p12-p22 (D8S133, NEFL, D8S131, D8S137, D8S339, D8S259, D8S505) and of allelic loss around the genes BRCA1 (Dl 7S855) and BRCA2 (D13S289) are
shown for paired normal (N) and tumour (T) specimens. Arrows indicate the alleles showing loss
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A Whether the broad centromeric region ofLOH actually contains
different minimal regions of loss for either familial or sporadic
MS 1 10 20 30 Tumours breast tumours remains unclear. Several of the familial and
D8S133 DDIDIDWJFIIJDDDIUUI UID IUD sporadic tumours analysed in this study appear to have a complex
NEFL n 8p LOH pattern, which may reflect a high degree of genomic
D8S131 *.ne.mmnenuurununennnnnnmnu instability in this genome region. This complicates the definition mmMlmEmuMEmmuu3u7um
mc of the exact region targeted by the deletional processes. D8S137 IIDONIDDIIEEDEDHUIDGIIIJDDUIUIIGIDG Alternatively, this may suggest that the presence of multiple
D8S339 G FDJIIIIOHDDIUIIAEDIUIIE targets in this region affected in the present study, which was the
D8S259 DUGODGUDDIDUDDEQIJEUDIIIIIDADGIE first to investigate microdissected familial tumours, clearly
D8S505 GDIDINDDDDGIGDDGIIDDDUDGDDDGDIIDIGDDD demonstrate the involvement of this genome region in familial
breast cancer.
I*Loss n Informative, no loss Not informative The apparent overlap of LOH in sporadic tumours suggests this
B region to be also important for the development ofbreast cancer in
non-familial cases.
MS 1 10 20 Tumours The regions of loss on 8pl2-p22 that we describe are in agree-
D85133 IoIIIIDIII IDOIDI IIO IUI IDIIIDIDI ment with recent reports on sporadic breast cancer (Chuaqui et al,
NEFL 1995; Kerangoueven et al, 1995; Imbert et al, 1996; Yaremko et al, DDIDIIDUIIIEJIIIDDUIIDIDIDDIEIID 1996) and are compatible with those ofprevious reports on other
D8S131 IDEIDfED IDIDJIID IDID tumour types, suggesting that one or more tumour-suppressor
D8S137 IDIIIJIDOIIIIDDDUIDDIIUIODIIIDUUD genes on 8p may play a role in the development ofmany common
D85339 IDDIDDUIDOUDUIIIDDIOIIDODDUII solid tumours (Emi et al, 1992; Yaremko et al, 1994; Macoska et D8S339 alll flflflflflflElflRflflff l
, 1995; Takle et al, 1996; Vocke et al, 1996).
E E8S259UEUUUUUUUEEUUUEUUUUUUUUUE Allelic loss on 8p has been shown to be associated with
D8S505 1IIIIIIIIODIDIDIIDDDUIDDIIDUII 1DI O advanced clinical stage in prostate (Suzuki et al, 1995), colon
(Tanaka et al, 1996), bladder (Knowles et al, 1993) and hepato-
Loss n Informative, no loss Not informative cellular (Emi et al, 1992) carcinoma. In breast cancer, the results
of such studies have been few and are rather contradictory.
C Yaremko et al (1995) demonstrated in an unselected series of human breast cancers that 8p LOH occurs with equal frequency
100 in large and small early-stage breast tumours, and they did not
90 find any correlation between 8p LOH and the ability of the
80 tumour to metastasize. These findings suggest that 8p LOH may
70 be an early event in breast carcinogenesis. In a following paper,
S 60 the same group compared the frequency of 8p LOH in invasive
9 50 > ductal carcinomas (IDC) with that of intraductal carcinomas
40 using markers D8S254, D8S133 and NEFL, this time finding a
30o significant correlation between 8p LOH and invasive behaviour
20 (Yaremko et al, 1996).
10 It has been suggested that LOH in familial tumours could, to a
greater extent, involve regions likely to harbour tumour-predis- 0
D8S133 NEFL D8S131 D8S137 D8S339 D8S259 D8S505 posing genes and, to a lesser extent, genes involved in tumour
progression (Lindblom et al, 1993). Based on this hypothesis, we
Figure 2 Loss of heterozygosity on the chromosome region 8p in familial have analysed the 8p LOH pattern in microdissected tissues of
and sporadic breast tumours. (A) Schematic representation of LOH analysis non-invasive and invasive breast tumours. We could not find a
of seven 8p microsatellite (MS) markers in 36 samples of familial breast significant difference in the LOH frequencies between both
cancer. (B) Schematic representation of LOH analysis of the MS markers
used in A in 31 samples of sporadic breast cancer. (C) Incidence (in %) of tumour types (100% vs 83.8% LOH). Therefore, 8p loss cannot be
LOH at the seven MS markers from chromosome region 8p unequivocally implicated as an early or late event in breast
carcinogenesis.
On the basis ofthe high frequency of 8p LOH in familial breast
DISCUSSION cancer, we conducted linkage analysis in four breast cancer fami-
lies who were most likely unlinked to either BRCA1 and BRCA2.
In this study of breast cancers from families with a high incidence Using the same marker sets used for LOH studies, a location score
of this disease, we have identified a very high frequency of 86.4% of 13.67 was obtained. Our results considerably strengthen earlier
of cumulative LOH involving the chromosome region 8pl2-p22. suggestions of a third breast cancer susceptibility gene on prox-
This exceeds the rate of LOH (74%) in a cohort ofsporadic breast imal 8p between the markers NEFL and D8S505 (Kerangoueven
tumours studied with the same marker set. et al, 1995; Imbert et al, 1996). These data were based mainly on
The two most frequently deleted regions in familial tumours cumulative linkage analysis of eight French families, whose indi-
were located at marker D8S133 (8p2l.1-pter) and more vidual LOD scores did not significantly exceed 0.5 for NEFL and
centromerically between D8S137 and D8S339 (Figure 1). In D8S259. In our analysis, the maximum multipoint LOD score of
sporadic tumours, a similarpatternofloss was observed. 2.32 was obtained at 0 = 0.00 for family 60 (Seitz et al, 1997).
British Journal ofCancer(1997) 76(8), 983-991 0CancerResearch Campaign 1997Chromosome region 8p12-p22 in breast cancer 989
Table 3 Loss of heterozygosity in familial breast cancer
Family number ID LOH at 8p12-p22 LOH at BRCA2 LOH at BRCA1
MDC29 300 + +
MDC30 300 +
303 + - +
MDC31 300a + 0
301a + +
302a + +
MDC32 300
MDC36 300 + +
MDC38 300 +
MDC39 300 + +
304 _
MDC42 301 + 0
MDC44 300 + NT +
MDC52 300 + 0 +
302 + 0 +
MDC56 300 + NT NT
MDC58 301 + 0 +
MDC59 300 + NT NT
302 + + NT
MDC60 302 +
401 + NT NT
402 + NT NT
415 + +
416 + NT
MDC64 203 + NT
300 + + +
MDC65 300 + NT NT
MDC67 300 + NT NT
MDC71 306 NT NT
MDC73 300 + + +
MDC74 300 + +
MDC75 300 + 0 +
MDC79 300 + - +
203 + + +
MDC81 302 + +
MDC94 300 + +
307 + NT NT
MDC95 300 + + +
MDC101 200 + + +
300 + + +
MDC102 302 + + +
MDC106 200 + +
306 +
MDC1363 302 + +
X=29 £=44 £=44 £=33 I=35
£1=44 £=28 £I=34
LOH =38 LOH =14 LOH =22
LOH % = 86.4% LOH% = 50.0% LOH% = 64.7%
a Male breast cancer. LOH, loss of heterozygosity; I, informative; NT not tested; +, loss; -, retention; 0, not informative.
Table 4 Frequencies of loss of heterozygosity at chromosome region 8p12-p22 in familial and sporadic breast carcinomas
D8S133 NEFL D8S131 D8S137 D8S339 D8S259 D8S505
Tumours T/NLOH/LOH% T/l/LOH/LOH% T/l/LOH/LOH% T/I/LOH/LOH% T/I/LOH/LOH% T/I/LOH/LOH% T/I/LOH/LOH%
Familial 28/25/13/52 43/26/9/35 35/31/16/52 35/26/14/54 42/27/13/48 35/24/8/33 33/25/4/16
breast
tumours
Sporadic 46/44/21/48 44/39/16/41 43/34/12/35 44/40/18/45 50/41/16/39 43/40/9/22 41/38/8/21
breast
tumours
T, tested; I, informative; LOH, loss of heterozygosity.
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Table 5 Linkage analysis in German breast cancerfamilies
Family number Three-point LOD score Three-point LOD score Multipoint LOD score for linkage
for linkage to BRCA1 for linkage to BRCA2 to chromosome region 8pI2-p22
MDC100a -0.11 -0.50 -0.22
MDC102 - 0.05 - 0.19 - 0.17
MDC106 -0.01 -0.84 -0.28
MDC107a - 0.73 -0.68 -0.62
MDC11a -0.02 -0.67 -0.20
MDC13a -0.19 -0.25 -0.28
MDC20a -0.24 -0.24 0.20
MDC37a -0.11 -0.46 -0.22
MDC38 - 0.04 - 0.17 - 0.15
MDC59 - 0.18 - 0.18 0.58
MDC60 - 1.95 - 2.12 2.32
MDC81 - 0.17 - 0.88 0.29
aNo tumour material available.
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Figure 3 Multipoint linkage analysis of families 20, 59, 60 and 81 around
the chromosome region 8p flanked by NEFL and D8S259 using Vitesse. The
LOD score is marginally significant (Z= location score 13.67) at D8S137.
The steep descent to D8S339 is due to a recombinant in family 60, the same
holds for D8S133 (not shown here) located telomeric to NEFL
Whether the putative tumour-su'ppressor gene is identical to such
gene(s) suggested for frequently deleted 8p regions is, in spite of
regional overlap, unknown.
While previously there were no obvious candidate genes in this
region, recently a putative helicase has been identified less than
I Mb centromeric of D8S339. Germline mutations of this gene
(WRN) have been detected in a number ofpatients with Werner's
syndrome, a disease characterized by premature ageing and an
increased incidence of neoplasms, including breast cancer (Yu
et al, 1996). Furthermore, Bruskiewich et al (1996) genetically
mapped the gene for the luteinizing hormone-releasing hormone
(LHRH) to a region bounded proximally by D8S137 and distally
by D8S136. LHRH is akey neuroendocrine molecule in the hypo-
thalamic-pituitary-gonadal hormonal system and impaired func-
tion of this hormone may also influence tumour cell proliferation
(Irmer et al, 1995; Bruskiewich et al, 1996).
Whether these or another as yet unknown gene on chromosome
band 8pl2-p22 will prove to be the putative breast cancer suscep-
tibility gene(s) remains to be elucidated.
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